|
|
|
|
| LEADER |
02511cam a2200325uu 4500 |
| 001 |
174664d3-2983-4f4f-ba97-b8af2f1ef216 |
| 003 |
miami |
| 005 |
20160318 |
| 007 |
c||||||||||||a| |
| 008 |
120805e20120805||||||||||#s||||||||eng|||||| |
| 024 |
7 |
|
|a urn:nbn:de:hbz:6-79379590027
|2 urn
|
| 041 |
|
|
|a eng
|
| 082 |
0 |
|
|a 330 Wirtschaft
|2 23
|
| 100 |
1 |
|
|a Festel, Gunter
|u FB 12: Chemie und Pharmazie
|0 http://d-nb.info/gnd/123291399
|4 aut
|
| 110 |
2 |
|
|a Universitäts- und Landesbibliothek Münster
|0 http://d-nb.info/gnd/5091030-9
|4 own
|
| 245 |
1 |
0 |
|a R&D Spin-outs in the pharmaceutical industry
|
| 250 |
|
|
|a [Electronic ed.]
|
| 264 |
|
1 |
|c 2011
|
| 264 |
|
2 |
|b Universitäts- und Landesbibliothek Münster
|c 2012-08-05
|
| 300 |
|
|
|a 101-113
|
| 500 |
|
|
|a Section "Research Paper"
|
| 506 |
0 |
|
|a free access
|
| 520 |
3 |
|
|a The high number of research and development (R&D) spin-outs in the pharmaceutical industry during the last 10 years focusing on drug development or offering specialised services demonstrates that pharmaceutical companies believe, through doing this, they can improve R&D performance. In a study, 43 European drug development as well as service oriented R&D spin-outs were analysed with regard to background, impact, realisation and the underlying strategy of the pharmaceutical parent companies. Spin-out creation can help to refocus the company strategy. Following a merger or simply complementing a strategic realignment on core areas, spin-outs provide a valuable option to leverage assets of low strategic importance, or under-exploited assets in their parent companies. Key aspects are strengthening the entrepreneurial spirit, a clear focus on core activities, performance-oriented controlling through cash-driven key indicators, high identification with the company, and appropriate financial incentives for management and staff.<br><br><br>
|
| 540 |
|
|
|a InC 1.0
|u https://rightsstatements.org/vocab/InC/1.0/
|
| 655 |
|
7 |
|2 DRIVER Types
|a Artikel
|
| 655 |
|
7 |
|2 DCMI Types
|a Text
|
| 700 |
1 |
|
|a De Cleyn, Sven H.
|u FB 12: Chemie und Pharmazie
|0 http://d-nb.info/gnd/131809199
|4 aut
|
| 773 |
1 |
|
|t Journal of Business Chemistry
|g 8 (2011) 3, S. 101-113
|i IsPartOf
|w (miami)30ea0d44-f69a-4d4b-947c-e84260d58208
|
| 856 |
4 |
0 |
|3 Zum Volltext
|q text/html
|u https://nbn-resolving.de/urn:nbn:de:hbz:6-79379590027
|u urn:nbn:de:hbz:6-79379590027
|
| 856 |
4 |
0 |
|3 Zum Volltext
|q application/pdf
|u https://repositorium.uni-muenster.de/document/miami/174664d3-2983-4f4f-ba97-b8af2f1ef216/2011_vol-8_iss3_101-113.pdf
|
